Literature DB >> 26906302

Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid Deposit After Anti-Tumor Necrosis Factor α Therapy in a Patient With Ankylosing Spondylitis.

Yu Ho Lee1, Eun Young Kim, Da Wun Jeong, Yang-Gyun Kim, Sang-Ho Lee, Ran Song, Hyung In Yang, Sung Jig Lim, Ju-Young Moon, Sang-Hoon Lee.   

Abstract

In secondary amyloid A amyloidosis resulting from rheumatologic diseases, tumor necrosis factor α blockers have been reported to be effective in the treatment of both arthritis and amyloidosis. However, there have been few reports concerning the alterations of renal tissue histology before and after long-term tumor necrosis factor α blockers therapy in secondary renal amyloidosis. We report the histological change after tumor necrosis factor α blocker therapy in patient with amyloid A amyloidosis and nephrotic syndrome secondary to underlying ankylosing spondylitis. The patient achieved complete remission of nephrotic syndrome after 17 months of etanercept treatment. We performed the second kidney biopsy after 40 months, and there was little change in the degree of amyloid deposition in the mesangial area and capillary loops compared with the first biopsy. The interstitial inflammation and foot process effacement, however, were fully recovered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26906302     DOI: 10.1097/RHU.0000000000000356

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  2 in total

1.  Spectrums and Prognosis of Kidney Disease in Patients with Ankylosing Spondylitis.

Authors:  Dafeng He; Rong Wang; Shaoshan Liang; Dandan Liang; Feng Xu; Caihong Zeng; Zheng Tang
Journal:  Kidney Dis (Basel)       Date:  2020-08-26

2.  Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence.

Authors:  Ozan Volkan Yurdakul; Abdulkerim Furkan Tamer; Okan Küçükakkaş; Aylin Rezvani
Journal:  Case Rep Rheumatol       Date:  2018-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.